

QED Bioscience Inc.

ADVANCED RESEARCH TECHNOLOGIES

Anti-MADD Antibody

ORDERING INFORMATION

Catalog No.: 1150

Size: 100 ug IgG in PBS, pH 7.4, purified by immunoaffinity chroma-tography.

BACKGROUND

MAP kinase-activating death domain protein (MADD) was initially identified as the type 1 tumor necrosis factor receptor (TNFR1). Overexpression of MADD activates MAP kinases ERK and JNK and induces the phosphorylation of cytosolic phospholipase A2. MADD shares 98% homology with DENN (differentially expressed in neoplastic vs. normal cells) which was recently identified as a substrate for c-jun N-terminal kinase 3 (JNK3). MADD has greater than 94% homology with a GDO/GTP exchange protein, Rab3-GEP, and it is 87% homologous with KIAA0358, a brain protein of unknown function. Identification of MADD as a component of the TNFR1 signalling complex and the similarity between MADD and Rab3-GEP provides a connection between TNFR1 activation and downstream MAP kinase activity through a guanine-nucleotide exchange protein.

For in vitro investigational use only. Not for use in therapeutic or diagnostic procedures.

SPECIFICATION SUMMARY

Antigen: Peptide corresponding to aa 1570-1588 of human MADD. This peptide sequence is identical to that of DENN and differs by one amino acid with rat GDP/GTP exchange protein RAB3-GEP.

Host Species: Rabbit

Stabilizers: None

Preservatives: 0.02% sodium azide.

SPECIFICITY

This antibody recognizes human and mouse MADD (200-220 kD).

APPLICATIONS

Immunoblotting: use at 1:250-1:500 dilution.

Positive control: Whole cell lysate from HeLa or NIH3T3 cells.

DILUTION INSTRUCTIONS

Dilute in PBS or medium which is identical to that used in the assay system.

STORAGE AND STABILITY

This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles.